Graves Disease Market: Pharma Pipeline Fuels Rapid Expansion by 2034 - DelveInsight

The Graves Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Graves Disease pipeline products will significantly revolutionize the Graves Disease market dynamics.

DelveInsight's "Graves Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Graves Disease, historical and forecasted epidemiology as well as the Graves Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Graves Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Graves Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Graves Disease Market Insights
https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Graves Disease Market Report:
• The Graves Disease market size was valued ~USD 4,400 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In May 2025, Amgen announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved TEPEZZA® (teprotumumab) for marketing, marking it as the first therapy specifically approved for adult patients with moderate-to-severe Thyroid Eye Disease (TED).
• In May 2025, Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases, announced that the U.S. FDA has granted Breakthrough Therapy Designation to veligrotug ("veli"), its lead anti-IGF-1R candidate for treating thyroid eye disease (TED).
• In January 2025, Sling Therapeutics, Inc., a late-stage biopharmaceutical company developing oral treatments for thyroid eye disease (TED), reported topline efficacy and safety results from its Phase 2b/3 LIDS trial evaluating linsitinib in patients with active, moderate-to-severe TED. Linsitinib, the company's lead oral small-molecule therapy administered twice daily, targets the IGF-1R pathway. It has shown a favorable safety profile, having been studied in over 900 patients across 15 clinical trials for various conditions.
• In 2023, there were approximately 7,134,600 total prevalent cases of Graves' disease across the 7MM. The prevalence of the condition in Japan is notably lower compared to Europe and the United States.
• In the 7MM, the US represented around 48% of the total prevalent cases of Graves' disease in 2023, while EU4 and the UK accounted for 46%, and Japan made up 6%.
• According to DelveInsight's estimates, approximately 3,720,200 diagnosed prevalent cases of Graves' disease were reported in the 7MM in 2023.
• In 2023, Graves' Ophthalmopathy accounted for the highest number of Graves' disease cases in the US, with approximately 584,400 reported cases.
• In 2023, the diagnosed prevalent cases of Graves' disease in Japan were around 80,450 in males and approximately 321,800 in females.
• Some of the promising emerging candidates include veligrotug (VRDN-001), VRDN-003, batoclimab, Efgartigimod PH20 SC, ENSPRYNG (satralizumab, RG6168), LASN01, linsitinib, AP-PA02, and Lonigutamab (anti-IGF-1R), among others.
• Key Graves Disease Companies: Amgen (Horizon Therapeutics), Immunovant, Samsung Biologics, HanAll Biopharma, and Roivant Sciences, Viridian Therapeutics, ACELYRIN, Novartis, AdvanceCor, Apitope, Worg Pharmaceuticals, AV7 Limited, and others
• Key Graves Disease Therapies: TEPEZZA (Teprotumumab-Trbw), IMVT-1401 (batoclimab, RVT-1401), VRDN-001 (veligrotug), Lonigutamab, Secukinumab, Cyclopeptides, ATX-GD-59, K1-70, and others
• The Graves Disease epidemiology based on gender analyzed that the Graves' Disease is 7-8 times more common in women than men

Graves Disease Overview
Graves' disease is an autoimmune disorder that affects the thyroid gland, a small butterfly-shaped gland located in the front of the neck. In Graves' disease, the immune system mistakenly attacks the thyroid gland, causing it to produce excessive amounts of thyroid hormones (hyperthyroidism).

Get a Free sample for the Graves Disease Market Report -
https://www.delveinsight.com/report-store/graves-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Graves Disease Market
The dynamics of the Graves Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
"The DAVIAD project successfully resulted in the manufacture GMP grade ATX-GD-59 and completion of pharmacodynamic and toxicology studies in order to progress the therapeutic vaccine into a Phase I/IIa clinical trial. In the clinical trial, the vaccine was proven to be safe and well tolerated."

Graves Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Download the report to understand which factors are driving Graves Disease epidemiology trends @ Graves Disease Epidemiological Insights
https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Graves Disease Epidemiology Segmentation:
The Graves Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Graves Disease
• Prevalent Cases of Graves Disease by severity
• Gender-specific Prevalence of Graves Disease
• Diagnosed Cases of Episodic and Chronic Graves Disease

Graves Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Graves Disease market or expected to get launched during the study period. The analysis covers Graves Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Graves Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

To know more about Graves Disease treatment, visit @ Graves Disease Medications
https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Graves Disease Therapies and Key Companies
• Secukinumab: Novartis
• Cyclopeptides: AdvanceCor
• ATX-GD-59: Apitope/ Worg Pharmaceuticals
• K1-70: AV7 Limited

Graves Disease Market Drivers
• Increasing in the prevalence of Graves Disease
• Increased public awareness about the treatment of Graves' disease

Graves Disease Market Barrriers
• High cost of the treatment
• Complications associated with the treatment

Scope of the Graves Disease Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Graves Disease Companies: Amgen (Horizon Therapeutics), Immunovant, Samsung Biologics, HanAll Biopharma, and Roivant Sciences, Viridian Therapeutics, ACELYRIN, Novartis, AdvanceCor, Apitope, Worg Pharmaceuticals, AV7 Limited, and others
• Key Graves Disease Therapies: TEPEZZA (Teprotumumab-Trbw), IMVT-1401 (batoclimab, RVT-1401), VRDN-001 (veligrotug), Lonigutamab, Secukinumab, Cyclopeptides, ATX-GD-59, K1-70, and others
• Graves Disease Therapeutic Assessment: Graves Disease current marketed and Graves Disease emerging therapies
• Graves Disease Market Dynamics: Graves Disease market drivers and Graves Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Graves Disease Unmet Needs, KOL's views, Analyst's views, Graves Disease Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.